Ā | Training group (Nā=ā99) | Testing group (Nā=ā97) | P value | |||
---|---|---|---|---|---|---|
Age (yrs.) | 45.9āĀ±ā13.35 | 46.64āĀ±ā15.90 | 0.961 | |||
ā <ā30 | 17(17.2%) | 14(14.4%) | Ā | |||
Ā 30ā50 | 35(35.4%) | 40(41.2%) | Ā | |||
ā >ā50 | 47(47.5%) | 43(44.3%) | Ā | |||
Ki-67 expression (%) | 32.37āĀ±ā28.01 | 25.05āĀ±ā26.35 | 0.946 | |||
Ā ā<ā50 | 59(67.0%) | 74(84.1%) | Ā | |||
Ā 50ā75 | 20(22.7%) | 5(5.7%) | Ā | |||
ā >ā75 | 9(10.2%) | 9(10.2%) | Ā | |||
CA-125 level(IU/L) | 553.32āĀ±ā994.28 | 300.30āĀ±ā452.27 | 0.000 | |||
ā <ā35 | 15(22.7%) | 18(27.7%) | Ā | |||
Ā 35ā200 | 17(25.8%) | 24(36.9%) | Ā | |||
Ā 200ā500 | 13(19.7%) | 10(15.4%) | Ā | |||
Ā ā>ā500 | 21(31.8%) | 13(20.0%) | Ā | |||
Category | Ā | Ā | 0.980 | |||
Ā Borderline tumor | 47(47.5%) | 44(45.4%) | Ā | |||
Ā Malignancies | 52(52.5%) | 53(54.6%) | Ā | |||
Ā Endometroid cancer | 2(2.0%) | 1(1.0%) | Ā | |||
Ā Low-grade adenocarcinoma | 0(0.0%) | 3(3.1%) | Ā | |||
Ā Clear cell type | 1(1.%) | 4(4.1%) | Ā | |||
Ā Serous carcinoma | 45(45.5%) | 38(39.2%) | Ā | |||
Ā Mucinous carcinoma | 2(2.0%) | 5(5.2%) | Ā | |||
Ā Mixed carcinoma | 2(2.0%) | 2(2.1%) | Ā |